Is cryosurgical ablation appropriate for treating hepatocellular cancer?

Area of Science:

• Hepatobiliary surgery
• Interventional oncology
• Cryoablation techniques

Background:

• Hepatocellular carcinoma (HCC) is a common primary liver cancer, often diagnosed in patients with underlying cirrhosis.
• Unresectable HCC poses a significant treatment challenge, necessitating exploration of alternative therapeutic modalities.
• Cryosurgical ablation offers a minimally invasive approach for tumor destruction.

Purpose of the Study:

• To evaluate the feasibility and efficacy of cryosurgical ablation for unresectable HCC in cirrhotic patients.
• To assess perioperative complications and survival outcomes associated with this treatment.

Main Methods:

• Retrospective case series involving 12 patients with cirrhosis and unresectable HCC across various stages.
• Cryosurgical ablation was performed on all identifiable tumors.
• Survival analysis included 9 patients treated with curative intent and 3 for palliation; 5 received preoperative chemoembolization.

Main Results:

• No perioperative deaths occurred; one patient experienced pneumonia and biloma post-procedure.
• Mean survival was 19 months post-ablation and 29 months post-diagnosis.
• Two patients with stage II HCC remain recurrence-free at 10 and 32 months, indicating potential for cure in select cases.

Conclusions:

• Cryosurgical ablation is a feasible and safe treatment option for HCC in patients with cirrhosis.
• The procedure demonstrates primarily palliative benefits but holds promise for curative outcomes in lower-stage HCC.
• Further research may elucidate optimal patient selection for cryoablation in HCC management.